Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia ...

About two million Americans will be diagnosed with cancer this year. It’s a disease that has impacted just about all of us in ...

says a variety of children require tube feeding for a number of reasons, and warns against rigid restrictions. “As a nurse, I can tell you that no patient is the same,” Ramsey tells CTV News.

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...

A prostate cancer patient said a national screening programme could have detected his cancer before it became incurable. John Gidman, 61, from Bracebridge Heath, Lincolnshire, was diagnosed with ...

Yet when Giusti sat down to write a book about her experience and to give advice to other cancer patients, drawing on nearly 30 of her own personal journals, her first instinct was not to feel a ...

Patients are often assured they no longer need to use additional forms of birth control. In 2019, a woman who got pregnant after both her fallopian tubes were removed said that she had been told the ...

Experts from the University’s School of Medicine have revealed that the Cancer Aging Research Group (CARG) score – a tool used to estimate the risk of severe chemotherapy-related side effects for ...

"This new way to treat gliomas could offer a potential lifeline for patients," Prof Jenkins, also head of the immunotherapy program at The Brain Cancer Center, said. "Our research has shown that ...

Cardiovascular death occurred in 15.8% of the patients in the invasive-strategy group and 14.2% of the patients in the conservative-strategy group (hazard ratio, 1.11; 95% CI, 0.86 to 1.44).

ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase ...